Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients
Top Cited Papers
Open Access
- 1 April 2006
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 17 (4) , 1181-1191
- https://doi.org/10.1681/asn.2005090997
Abstract
Although treating anemia of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve survival, most studies have examined associations between baseline hemoglobin values and survival and ignored variations in clinical and laboratory measures over time. It is not clear whether longitudinal changes in hemoglobin or administered ESA have meaningful associations with survival after adjustment for time-varying confounders. With the use of time-dependent Cox regression models, longitudinal associations were examined between survival and quarterly (13-wk averaged) hemoglobin values and administered ESA dose in a 2-yr (July 2001 to June 2003) cohort of 58,058 maintenance hemodialysis patients from a large dialysis organization (DaVita) in the United States. After time-dependent and multivariate adjustment for case mix, quarterly varying administered intravenous iron and ESA doses, iron markers, and nutritional status, hemoglobin levels between 12 and 13 g/dl were associated with the greatest survival. Among prevalent patients, the lower range of the recommended Kidney Disease Quality Outcomes Initiative hemoglobin target (11 to 11.5 g/dl) was associated with a higher death risk compared with the 11.5- to 12-g/dl range. A decrease or increase in hemoglobin over time was associated with higher or lower death risk, respectively, independent of baseline hemoglobin. Administration of any dose of ESA was associated with better survival, whereas among those who received ESA, requiring higher doses were surrogates of higher death risk. In this observational study, greater survival was associated with a baseline hemoglobin between 12 and 13 g/dl, treatment with ESA, and rising hemoglobin. Falling hemoglobin and requiring higher ESA doses were associated with decreased survival. Randomized clinical trials are required to examine these associations.Keywords
This publication has 36 references indexed in Scilit:
- Time-Dependent Associations between Iron and Mortality in Hemodialysis PatientsJournal of the American Society of Nephrology, 2005
- Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney diseaseKidney International, 2005
- Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis PopulationHypertension, 2005
- Presence of a Failed Kidney Transplant in Patients Who Are on Hemodialysis Is Associated with Chronic Inflammatory State and Erythropoietin ResistanceJournal of the American Society of Nephrology, 2004
- Pentoxifylline Improves Hemoglobin Levels in Patients with Erythropoietin-resistant Anemia in Renal FailureJournal of the American Society of Nephrology, 2004
- Haemoglobin and haematocrit targets for the anaemia of chronic kidney diseasePublished by Wiley ,2003
- Erythropoietin and anemiaSeminars in Nephrology, 2001
- Role of Cytokines in the Pathogenesis of Anemia of Chronic Disease in Rheumatoid ArthritisClinical Immunology, 1999
- Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietinAmerican Journal of Kidney Diseases, 1996
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990